{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:32:22Z","timestamp":1791858742282,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3323,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1038\/sj.ki.5001868","type":"journal-article","created":{"date-parts":[[2006,10,4]],"date-time":"2006-10-04T15:23:47Z","timestamp":1159975427000},"page":"1858-1865","source":"Crossref","is-referenced-by-count":300,"title":["Mortality risk among hemodialysis patients receiving different vitamin D analogs"],"prefix":"10.1016","volume":"70","author":[{"given":"F.","family":"Tentori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Medical Directors of Dialysis Clinic Inc.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.C.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Stidley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Rohrscheib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Bedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.B.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.ki.5001868_bb0010","series-title":"US Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-stage Renal Disease in the United States.","article-title":"National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease","year":"2004"},{"key":"10.1038\/sj.ki.5001868_bb0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/ajkd.2001.29250","article-title":"Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients","volume":"38","author":"Kalantar-Zadeh","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0020","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","article-title":"Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure","volume":"55","author":"Stenvinkel","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0025","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001868_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1523-1755.2001.060002472.x","article-title":"Pathophysiological mechanisms of vascular calcification in end-stage renal disease","volume":"60","author":"Davies","year":"2001","journal-title":"Kidney Int"},{"issue":"Suppl","key":"10.1038\/sj.ki.5001868_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1523-1755.62.s82.15.x","article-title":"Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon","volume":"82","author":"Qunibi","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0040","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001868_bb0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0050","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl","key":"10.1038\/sj.ki.5001868_bb0055","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1046\/j.1523-1755.63.s85.26.x","article-title":"Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population","volume":"85","author":"Marco","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0060","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001868_bb0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0272-6386(96)90396-0","article-title":"Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia","volume":"28","author":"Avram","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0070","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/ajkd.2001.29254","article-title":"Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation","volume":"38","author":"Avram","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1038\/sj.ki.5001868_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0080","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJM199810083391507","article-title":"Care of patients undergoing hemodialysis","volume":"339","author":"Ifudu","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001868_bb0090","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","article-title":"Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients","volume":"74","author":"Slatopolsky","year":"1984","journal-title":"J Clin Invest"},{"issue":"Suppl 10","key":"10.1038\/sj.ki.5001868_bb0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/17.suppl_10.10","article-title":"Vitamin D analogues for secondary hyperparathyroidism","volume":"17","author":"Brown","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001868_bb0100","first-page":"F157","article-title":"Vitamin D","volume":"277","author":"Brown","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1038\/sj.ki.5001868_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0110","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2","volume":"32","author":"Martin","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0115","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0120","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001868_bb0125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0135","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0140","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001868_bb0145","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001868_bb0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001868_bb0155","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1046\/j.1523-1755.2001.00029.x","article-title":"Association between prevalent care process measures and facility-specific mortality rates","volume":"60","author":"Lowrie","year":"2001","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0160","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1038\/sj.ki.5001868_bb0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","article-title":"Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Young","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001868_bb0170","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.505004","article-title":"Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid","volume":"206","author":"Stumpf","year":"1979","journal-title":"Science"},{"key":"10.1038\/sj.ki.5001868_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.ki.5000045","article-title":"Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation","volume":"69","author":"Andress","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1038\/sj.ki.5001868_bb0185","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000185191","article-title":"In vivo effect of 1 alpha-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients","volume":"50","author":"Tabata","year":"1988","journal-title":"Nephron"},{"key":"10.1038\/sj.ki.5001868_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000013569","article-title":"Calcitriol therapy modulates the cellular immune responses in hemodialysis patients","volume":"20","author":"Tokuda","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1038\/sj.ki.5001868_bb0195","doi-asserted-by":"crossref","first-page":"39394","DOI":"10.1074\/jbc.M502966200","article-title":"Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia","volume":"280","author":"Xiang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/sj.ki.5001868_bb0200","first-page":"2822","article-title":"20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines","volume":"55","author":"Elstner","year":"1995","journal-title":"Cancer Res"},{"key":"10.1038\/sj.ki.5001868_bb0205","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1046\/j.1523-1755.1998.00152.x","article-title":"Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium","volume":"54","author":"Panichi","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0210","doi-asserted-by":"crossref","first-page":"35798","DOI":"10.1074\/jbc.M404865200","article-title":"Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice","volume":"279","author":"Aihara","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/sj.ki.5001868_bb0215","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0002-9440(10)65448-X","article-title":"Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack","volume":"154","author":"Zager","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1038\/sj.ki.5001868_bb0220","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1038\/sj.ki.5001868_bb0225","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001868_bb0230","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.288.19.2449","article-title":"Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis","volume":"288","author":"Devereaux","year":"2002","journal-title":"JAMA"},{"key":"10.1038\/sj.ki.5001868_bb0235","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/ajkd.2002.30552","article-title":"Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease","volume":"39","author":"Miskulin","year":"2002","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815517985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815517985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T20:34:27Z","timestamp":1627850067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815517985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0085253815517985"],"URL":"https:\/\/doi.org\/10.1038\/sj.ki.5001868","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}